DaVita stock just endured a 17% single day drop, yet the earnings story that triggered it looks far more measured. The company delivered adjusted earnings per share of US$4.02 in the quarter and reaffirmed full year adjusted earnings guidance around US$14.65. For a healthcare services stock that closed yesterday near US$228 and now trades around US$189, this is a sentiment shock focused less on an earnings miss and more on worries about long term margins and debt.

Is DaVita suddenly a 48% off value opportunity, or is this lower P/E simply the market pricing in softer growth and debt risk? Compare that gap yourself on the valuation analysis for DaVita

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$3,415.55m vs. US$3,379.53m (up about 1.1%)
• Net Income, Q2 2026 vs. Q2 2025: US$197.53m vs. US$199.34m (slightly lower)
• Basic EPS, Q2 2026 vs. Q2 2025: US$2.93 vs. US$2.62 (up about 10.9%)
• Trailing 12-month Basic EPS, Q2 2026 vs. Q2 2025: US$10.62 vs. US$10.43 (up about 1.8%)

Tired of scrolling through long earnings tables and raw figures trying to piece together what just happened with DaVita? See the full financial picture in a clean visual format, with valuation front and center, in the company report for DaVita.

Evaluating DaVita’s Earnings Momentum Story

The bullish view on DaVita is that better clinical outcomes, technology and Integrated Kidney Care can steadily lift volumes, margins and free cash flow. Q2 results partially support that. U.S. dialysis treatments per normalized day grew about 56 bps and management now expects full year treatments near the top of prior guidance. Management directly links this to improving mortality, which matches the narrative that clinical performance, not just pricing, drives growth.

On profitability, the picture is more mixed for the bull case. Adjusted operating income of US$579m and free cash flow of US$256m sit in line with a reaffirmed full year EPS midpoint of US$14.65. That suggests no visible step up yet from technology or AI efficiencies. Revenue per treatment is up 3.6% year to date, but guidance for only 1 to 2% growth for the year and higher year to date patient care costs show margin expansion milestones are not fully achieved.

Compare DaVita’s internal progress on volumes, revenue per treatment and reaffirmed EPS with how institutions are reacting to the 17% share price drop. See whether Wall Street is raising or cutting its targets in the consensus price target analysis for DaVita.

DaVita Bears See Margins, Mix And Debt Concerns Resurface

Bears argue that DaVita is carrying rising costs, reimbursement pressure and debt, with IT and Integrated Kidney Care spending delaying margin gains. Q2 results give that view some support. Revenue per treatment is up 3.6% year to date, yet full year guidance points to only 1 to 2% growth, which implies weaker pricing and mix in the second half after a sequential US$2 decline in Q2 tied to softer commercial mix and phosphate binder revenue.

Patient care costs per treatment are up more than 3% year to date and are now expected to grow 1.25 to 2.25% for the full year. That suggests only gradual cost relief, not a clear efficiency inflection from AI and IT. Incremental US$500m of debt and US$152m of quarterly interest expense keep leverage at 3.37x EBITDA, which limits flexibility if Integrated Kidney Care contributions or CMS reimbursement track below expectations.

With leverage already elevated and patient care costs running ahead of revenue per treatment, even small execution slips could matter a lot for DaVita. Review our independent risk analysis for DaVita which shows 2 important warning signs to see whether this margin pressure and debt load are just the start of deeper structural warning signs.

Stay Ahead With Simply Wall St

If the 17% single day drop in DaVita stock has you watching for a better entry point, register for free with Simply Wall St and add it to a Watchlist so you can track price against fair value without constantly checking the market. Once you decide to take or adjust a position, use the Portfolio Command Center to cut through noise and surface only the key updates that matter to your holdings. For a longer term view, tap into shared investor thinking through the Community and see how others are interpreting the same signals. By spotting potential catalysts and risk flags early, you can review information more quickly and stay a step ahead of the market.

Seeking Alternatives Beyond DaVita Stock?

Fresh ideas can move fast. Some stocks are building quiet momentum, while others are dropping into potential bargain territory. Check these curated lists before the crowd and consider getting in early.

• Spot companies with solid cash flows and balance sheets that could be lining up for their next breakout phase through the 50 high quality undervalued stocks.
• Explore the growth of AI adoption by checking out established businesses already turning algorithms into profits with the 67 profitable AI stocks that aren't just burning cash.
• Zero in on cash generative companies that pair resilience with cleaner financials using the list of solid balance sheet and fundamentals stocks (48 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.